GLPG2222 Plus Kalydeco Shows Positive Clinical Results in Phase 2 Trial, Galapagos Reports
Adding investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor), reported the therapy’s Belgian developer, Galapagos, citing Phase 2 clinical trial data. The benefit of adding GLPG2222 was similar to that seen in an earlier study of a tezacaftor-Kalydeco combination, researchers said.